SOURCE: Nivalis Therapeutics, Inc.

Nivalis Therapeutics, Inc. Logo

March 02, 2016 08:00 ET

Nivalis Therapeutics to Present at Two Upcoming Investor Conferences

BOULDER, CO--(Marketwired - March 02, 2016) - Nivalis Therapeutics, Inc. (NASDAQ: NVLS), a clinical stage pharmaceutical company focused on treating people with cystic fibrosis (CF), today announced that Chief Executive Officer Jon Congleton will present a corporate overview at the Cowen and Company 36th Annual Health Care Conference and the 28th Annual ROTH Conference.

Details of the two presentations are as follows:

Cowen and Company 36 th Annual Health Care Conference
Date: Tuesday, March 8th
Location: The Boston Marriott Copley Place, Boston
Presentation Time: 10:40 AM EST

28 th Annual ROTH Conference
Date: Tuesday, March 15th
Location: The Ritz Carlton Laguna Niguel, Dana Point
Presentation Time: 2:30 PM PST

Individuals may access a live webcast of the conference presentations on the Nivalis website at www.nivalis.com under "IR Calendar" in the "News / Events" section. A replay of the webcast will be available on this site for 90 days following the live event.

About Nivalis Therapeutics, Inc.

Nivalis Therapeutics, Inc. (http://www.nivalis.com) is a clinical stage pharmaceutical company committed to the discovery, development and commercialization of therapeutics for people with CF. In addition to developing innovative solutions intended to extend and improve the lives of people with CF, Nivalis plans to utilize its proprietary S-nitrosoglutathione reductase (GSNOR) inhibitor portfolio to develop therapeutics for other diseases.

Contact Information